KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.

Mellema, Wouter W

KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. [electronic resource] - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Sep 2013 - 1190-5 p. digital

Publication Type: Journal Article; Multicenter Study

1556-1380

10.1097/JTO.0b013e318298764e doi


Adenocarcinoma--drug therapy
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carboplatin--administration & dosage
Carcinoma, Non-Small-Cell Lung--drug therapy
Cisplatin--administration & dosage
Docetaxel
Female
Follow-Up Studies
Glutamates--administration & dosage
Guanine--administration & dosage
Humans
Lung Neoplasms--drug therapy
Male
Middle Aged
Mutation--genetics
Neoplasm Staging
Pemetrexed
Prognosis
Proto-Oncogene Proteins--genetics
Proto-Oncogene Proteins p21(ras)
Retrospective Studies
Survival Rate
Taxoids--administration & dosage
Vinblastine--administration & dosage
Vinorelbine
ras Proteins--genetics